Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type

Annals of Oncology

Volumn 22, Issue 1, 2011, Pages 149-155

  Huang, J J ^a   Jiang, W Q ^a   Lin, T Y ^a   Huang, Y ^a   Xu, R H ^a   Huang, H Q ^a   Li, Z M ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Absolute lymphocyte count; Extranodal NK T cell lymphoma; Prognosis

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; OXALIPLATIN; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNE STATUS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NK T CELL LYMPHOMA; OUTCOMES RESEARCH; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 78650315593     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq314     Document Type: Article

References (39)

1. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Lyon: IARC 2008.
2. Aozasa K, Ohsawa M, Tajima K et al. Nation-wide study of lethal mid-line granuloma in Japan: frequencies of wegener's granulomatosis, polymorphic reticulosis, malignant lymphoma and other related conditions. Int J Cancer 1989; 44: 63-66.
3. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
4. Jaffe ES, Chan JK, Su IJ et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20: 103-111.
5. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-4130.
6. Kim TM, Park YH, Lee SY et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005; 106: 3785-3790.
7. Lee J, Suh C, Park YH et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612-618.
8. Aviles A, Diaz NR, Neri N et al. Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol 2000; 22: 215-220.
9. Cheung MM, Chan JK, Lau WH et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54: 182-190.
10. Cheung MM, Chan JK, Lau WH et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 70-77.
11. Chim CS, Ma SY, Au WY et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103: 216-221.
12. You JY, Chi KH, Yang MH et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004; 15: 618-625.
13. Au WY, Weisenburger DD, Intragumtornchai T et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113: 3931-3937.
14. Behl D, Ristow K, Markovic SN et al. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol 2007; 137: 409-415.
15. Siddiqui M, Ristow K, Markovic SN et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 2006; 134: 596-601.
16. Kim DH, Baek JH, Chae YS et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007; 21: 2227-2230.
17. De Angulo G, Yuen C, Palla SL et al. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer 2008; 112: 407-415.
18. Bari A, Marcheselli L, Sacchi S et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol 2009 Nov 17 [Epub ahead of print] doi:10.1093/annonc/mdp531.
19. Porrata LF, Gertz MA, Inwards DJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579-585.
20. Lee J, Kim WS, Park YH et al. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer 2005; 92: 1226-1230.
21. Lee J, Park YH, Kim WS et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005; 41: 1402-1408.
22. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
23. Gallamini A, Stelitano C, Calvi R et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474-2479.
24. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
25. Grillo-Lopez AJ, Cheson BD, Horning SJ et al. Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. Ann Oncol 2000; 11: 399-408.
26. Porrata LF, Ingle JN, Litzow MR et al. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2001; 28: 865-871.
27. Ray-Coquard I, Cropet C, Van Glabbeke M et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009; 69: 5383-5391.
28. Cox MC, Nofroni I, Ruco L et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 2008; 49: 1745-1751.
29. Behl D, Porrata LF, Markovic SN et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006; 20: 29-34.
30. Porrata LF, Litzow MR, Tefferi A et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002; 16: 1311-1318.
31. Logsdon MD, Ha CS, Kavadi VS et al. Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer 1997; 80: 477-488.
32. Li YX, Coucke PA, Li JY et al. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 1998; 83: 449-456.
33. Kim WS, Song SY, Ahn YC et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001; 12: 349-352.
34. Adami J, Gabel H, Lindelof B et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221-1227.
35. Curtis RE, Travis LB, Rowlings PA et al. Riskof lymphoproliferative disordersafterbone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208-2216.
36. Saito T, Kuss I, Dworacki G et al. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 1999; 5: 1263-1273.
37. Dworacki G, Meidenbauer N, Kuss I et al. Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 2001; 7: 947s-957s.
38. Ayoub JP, Palmer JL, Huh Y et al. Therapeutic and prognostic implications of peripheral blood lymphopenia in patients with Hodgkin's disease. Leuk Lymphoma 1999; 34: 519-527.
39. Borg C, Ray-Coquard I, Philip I et al. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004; 101: 2675-2680.